0.00Open18.54Pre Close0 Volume1 Open Interest40.00Strike Price0.00Turnover131.43%IV16.89%PremiumDec 20, 2024Expiry Date14.18Intrinsic Value100Multiplier23DDays to Expiry4.36Extrinsic Value100Contract SizeAmericanOptions Type-0.8733Delta0.0251Gamma1.83Leverage Ratio-0.0351Theta-0.0166Rho-1.60Eff Leverage0.0136Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet